entospletinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk). It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).   Wikipedia

Chemistry

  • SMILES: C1CN(CCO1)c2ccc(Nc3nc(cn4ccnc34)c5ccc6cn[nH]c6c5)cc2
  • InChIKey: XSMSNFMDVXXHGJ-UHFFFAOYSA-N
  • Mol. Mass: 411.47
  • ALogP: 3.85
  • ChEMBL Molecule:
    entospletinib  
More Chemistry

Pharmacology

Alternative names

6-(1h-indazol-6-yl)-n-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine | entospletinib | gs-9973

Organizations (11)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Anemia (Phase 1/Phase 2)

Graft vs Host Disease (Phase 2)

Healthy Volunteers (Phase 1)

Hematologic Neoplasms (Phase 1)

Leukemia, B-Cell (Phase 1)

Leukemia, Hairy Cell (Phase 1/Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Myeloid, Acute (Phase 3)

Leukemia, Prolymphocytic, B-Cell (Phase 1/Phase 2)

Lymphoma (Phase 1/Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 1/Phase 2)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 1/Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 1/Phase 2)

Neoplasms (Phase 1)

Pharmacokinetics (Phase 1)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 1)

Pulmonary Disease, Chronic Obstructive ()

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue